Biotech Values

[jq1234]

I'm not sure I understand why you think its misleading? It appears to question the market more than the drug while the bloomberg article appears to accept the analysts claims of a large market without questioning it.

It's misleading because it didn't clearly state what the drug is approved for in NYTimes while it is in Bloomberg:

From Bloomberg:

The medicine, Nuedexta, is the first approved to treat patients with multiple sclerosis or Lou Gehrig’s disease who develop symptoms known as pseudobulbar affect that causes loss of emotional control, the Food and Drug Administration said in a statement.

In addition, NYTimes blog quoted AVNR CEO regarding their estimate of overall population, not approved population for ALS and MS. It basically reinforced the author's opinion that the disease is sham, and the drug shouldn't be approved. So, you drew the same conclusion as the author. I don't blame you. I think most people who don't know the condition and AVNR would draw same conclusion as you did after reading it. The condition is already treated with other drugs off label.

Bloomberg article simply stated what the drug was approved for, and what one analyst's opinion of market potential. So nothing is hidden. Either you believe the analyst or you don't. The author didn't try to inject his own opinion. I don't mind author injecting his own opinion, I just hope he gives the fact first, then state clearly what his opinion is. In NYTimes article, it muddled the fact, then gave his opinion. That's the worst in my opinion.

By the way, I don't agree with the analyst's opinion on the size of market in ALS and MS.